'Capecitabine' diaporamas de présentation

Management of rectal cancer

Mediterranean School of Oncology Rome, November 23, 2012. Management of rectal cancer. CARMINE PINTO Oncologia Medica Policlinico S.Orsola-Malpighi Bologna. Background - 1.

1.17k views • 82 slides

Antineoplastics and Antianemics

Antineoplastics and Antianemics. Pharmacology NURS 1950. Objective 1: Describe the general factors utilized to select the therapy used to treat cancer Surgery Radiation Chemotherapy Most effective against rapidly growing cells.

1.1k views • 81 slides

A Report from ECCO 14 Oral Chemotherapy in Breast Cancer

A Report from ECCO 14 Oral Chemotherapy in Breast Cancer. William J. Gradishar, MD Director, Breast Medical Oncology Professor of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL.

451 views • 27 slides

Background

EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy ( capecitabine / oxaliplatin ) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk.

396 views • 24 slides

James Cassidy, MD Colorectal Cancer Update Think Tank Meeting June 24, 2005

424 views • 23 slides

Preoperative chemoradiotherapy WITH CVI 5FU is the standard of care for T3-4 rectal CANCER

The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04.

356 views • 19 slides

Authors: Hofheinz et al Reviewed By: Scott Berry Date posted: June 2011

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results of a randomized phase III trial. Authors: Hofheinz et al Reviewed By: Scott Berry Date posted: June 2011.

288 views • 16 slides

Lluch A et al. Proc SABCS 2010;Abstract P5-10-15.

First Safety Data from a Randomized Phase III (CIBOMA/2004-01/GEICAM 2003-11) Trial Assessing Adjuvant Capecitabine Maintenance Therapy After Standard Chemotherapy for Triple-Negative Early Breast Cancer. Lluch A et al. Proc SABCS 2010;Abstract P5-10-15. Study Design. Accrual: 816 (Open).

71 views • 7 slides

Capecitabine 2000mg d1-14 Q3wks x 6 cycles (n = 299)

Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907.

183 views • 6 slides